scholarly journals The influence of compression therapy on the level of inflammatory biomarkers in patients with chronic venous disease.

2021 ◽  
Vol 1 (1) ◽  
pp. 32-36
Author(s):  
Jedrzej Tkaczyk ◽  
Stanisław Przywara ◽  
Joanna Iłżecka ◽  
Marek Iłżecki
Keyword(s):  
Compression Therapy ◽  
Inflammatory Biomarkers ◽  
Chronic Venous Disease ◽  
Venous Disease

scholarly journals Why Venous Leg Ulcers Have Difficulty Healing: Overview on Pathophysiology, Clinical Consequences, and Treatment

2020 ◽  
Vol 10 (1) ◽  
pp. 29
Author(s):  
Joseph D. Raffetto ◽  
Daniela Ligi ◽  
Rosanna Maniscalco ◽  
Raouf A. Khalil ◽  
Ferdinando Mannello
Keyword(s):  
Endothelial Cell ◽  
Reactive Oxygen ◽  
Compression Therapy ◽  
Venous Hypertension ◽  
Chronic Venous Disease ◽  
Venous Disease ◽  
Leg Ulcers ◽  
Nitrogen Species ◽  
Venous Leg Ulcers ◽  
Tissue Metabolites

Venous leg ulcers (VLUs) are one of the most common ulcers of the lower extremity. VLU affects many individuals worldwide, could pose a significant socioeconomic burden to the healthcare system, and has major psychological and physical impacts on the affected individual. VLU often occurs in association with post-thrombotic syndrome, advanced chronic venous disease, varicose veins, and venous hypertension. Several demographic, genetic, and environmental factors could trigger chronic venous disease with venous dilation, incompetent valves, venous reflux, and venous hypertension. Endothelial cell injury and changes in the glycocalyx, venous shear-stress, and adhesion molecules could be initiating events in VLU. Increased endothelial cell permeability and leukocyte infiltration, and increases in inflammatory cytokines, matrix metalloproteinases (MMPs), reactive oxygen and nitrogen species, iron deposition, and tissue metabolites also contribute to the pathogenesis of VLU. Treatment of VLU includes compression therapy and endovenous ablation to occlude the axial reflux. Other interventional approaches such as subfascial endoscopic perforator surgery and iliac venous stent have shown mixed results. With good wound care and compression therapy, VLU usually heals within 6 months. VLU healing involves orchestrated processes including hemostasis, inflammation, proliferation, and remodeling and the contribution of different cells including leukocytes, platelets, fibroblasts, vascular smooth muscle cells, endothelial cells, and keratinocytes as well as the release of various biomolecules including transforming growth factor-β, cytokines, chemokines, MMPs, tissue inhibitors of MMPs (TIMPs), elastase, urokinase plasminogen activator, fibrin, collagen, and albumin. Alterations in any of these physiological wound closure processes could delay VLU healing. Also, these histological and soluble biomarkers can be used for VLU diagnosis and assessment of its progression, responsiveness to healing, and prognosis. If not treated adequately, VLU could progress to non-healed or granulating VLU, causing physical immobility, reduced quality of life, cellulitis, severe infections, osteomyelitis, and neoplastic transformation. Recalcitrant VLU shows prolonged healing time with advanced age, obesity, nutritional deficiencies, colder temperature, preexisting venous disease, deep venous thrombosis, and larger wound area. VLU also has a high, 50–70% recurrence rate, likely due to noncompliance with compression therapy, failure of surgical procedures, incorrect ulcer diagnosis, progression of venous disease, and poorly understood pathophysiology. Understanding the molecular pathways underlying VLU has led to new lines of therapy with significant promise including biologics such as bilayer living skin construct, fibroblast derivatives, and extracellular matrices and non-biologic products such as poly-N-acetyl glucosamine, human placental membranes amnion/chorion allografts, ACT1 peptide inhibitor of connexin 43, sulodexide, growth factors, silver dressings, MMP inhibitors, and modulators of reactive oxygen and nitrogen species, the immune response and tissue metabolites. Preventive measures including compression therapy and venotonics could also reduce the risk of progression to chronic venous insufficiency and VLU in susceptible individuals.

Initiating compression therapy for those living with heart failure

2021 ◽  
Vol 26 (Sup9) ◽  
pp. S12-S17
Author(s):  
Dumitriu Saucedo ◽  
Nicholas Evans ◽  
Chung Sim Lim
Keyword(s):  
Heart Failure ◽  
Compression Therapy ◽  
Decompensated Heart Failure ◽  
Chronic Venous Disease ◽  
Venous Disease ◽  
Evidence Based ◽  
Patients With Heart Failure ◽  
Precautionary Measures ◽  
Evidence Based Guideline ◽  
Nursing Professionals

Compression therapy is used to treat leg symptoms arising from chronic venous disease and lymphoedema. Heart failure, which is traditionally regarded as a contraindication for compression therapy, is prevalent among patients with such leg symptoms. This article aims to assess the evidence on the safety and effectiveness of compression therapy, as well as recommending the assessment and measures required when initiating compression therapy in patients with heart failure. Recent evidence suggests that initiating compression therapy in patients with stable and compensated heart failure is safe if appropriate precautionary measures are undertaken. However, there is still insufficient evidence to support the safety of compression therapy in patients with severe and decompensated heart failure. A standardised, evidence-based guideline on compression therapy in patients with heart failure will help medical and nursing professionals and improve informed consent for the patients.

The impact of compression garments on the quality of life in patients with chronic venous disease

Physiotherapy ◽  
2017 ◽  
Vol 24 (2) ◽  
Author(s):  
Iwona Demczyszak ◽  
Edyta Sutkowska ◽  
Magdalena Jasiak ◽  
Małgorzata Fortuna ◽  
Justyna Mazurek
Keyword(s):  
Quality Of Life ◽  
Lower Extremity ◽  
Compression Therapy ◽  
Chronic Venous Disease ◽  
Venous Disease ◽  
Compression Garments ◽  
Before And After ◽  
The Impact ◽  
Career Status

AbstractIntroduction. Assessment of quality of life in patients suffering from chronic venous disease of the lower extremity who were treated with compression garments. Methods. Patients of both sexes aged 30-75 years with chronic venous disease and at least varices, but without active ulceration, were qualified for the study. To assess the quality of life, the CIVIQ-20 questionnaire was used before and after 4 weeks of compression therapy with second class compression. Results. The combined results of the CIVIQ scale rose from 61.49% before compression to 75.17% after 4 weeks of compression therapy (p 0.01). No correlation was found between sex, age, career status or type of work and the averaged CIVIQ score. Conclusions. Compression therapy with special garments significantly improves the quality of life in patients with chronic venous disease. Larger studies are still needed in this field.

scholarly journals Circaid adjustable inelastic compression wraps for the treatment of lower limb edema in the venous system pathology

2019 ◽  
pp. 12-16
Author(s):  
A. Yu. Semenov ◽  
A. M. Malakhov
Keyword(s):  
Chronic Venous Insufficiency ◽  
Western Europe ◽  
Venous Insufficiency ◽  
Medical Science ◽  
Compression Therapy ◽  
European Population ◽  
Chronic Venous Disease ◽  
Venous Disease ◽  
Compression Garments ◽  
The Usa

Symptoms of chronic venous insufficiency have been known since antiquity. The prevalence of chronic venous insufficiency in Western Europe and the USA has been reported within the range from from 1 to 40% in women and from 1 to 17% in men [1]. As reported by the European authors, the average prevalence of chronic venous insufficiency with class C2-C6 (according to the CEAP classification) among the European population reaches 30% [2]. Edema syndrome remains one of the leading manifestations of chronic venous disease. Compression therapy is one of the main ways to combat edema. The arsenal of devices for the treatment of edematous syndrome is steadily expanding with the development of medical science. Today, in addition to inelastic compression wrap and elastic compression garments, brand-new compression products, circaid adjustable inelastic compression wraps are available.

The Contribution of Nutrition in Compression Therapy for Chronic Venous Disease

2020 ◽  
Vol 7 (3) ◽  
pp. 09-12
Author(s):  
Hendro Sudjono Yuwono ◽  
Dedy Pratama
Keyword(s):  
Mechanical Treatment ◽  
Pathological Change ◽  
Compression Therapy ◽  
Chronic Venous Disease ◽  
Venous Disease ◽  
Essential Step ◽  
Nutrition Intake ◽  
Mechanical Therapy

Compression therapy is an essential step for the treatment of chronic venous disease (CVD). It is a mechanical treatment against the venous wall's persistent pathological change and the CVD created by inner metabolic substances that damage the wall and valves. The damage is possible to prevent using flavonoid drug and daily nutrition intake, which support the mechanical therapy positively.

scholarly journals The effect of compression therapy on quality of life in patients with chronic venous disease: a comparative 6-month study

2020 ◽  
Author(s):  
Andrzej Berszakiewicz ◽  
Janusz Kasperczyk ◽  
Aleksander Sieroń ◽  
Zbigniew Krasiński ◽  
Armand Cholewka ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Compression Therapy ◽  
Chronic Venous Disease ◽  
Venous Disease

Compliance with compression therapy in primary chronic venous disease: Results from a tropical country

2018 ◽  
Vol 34 (4) ◽  
pp. 272-277 ◽  
Author(s):  
Álvaro Ayala ◽  
Jose D Guerra ◽  
Jorge H Ulloa ◽  
Lowell Kabnick
Keyword(s):  
Compression Therapy ◽  
Chronic Venous Disease ◽  
Venous Disease ◽  
Tropical Country ◽  
Time Compression ◽  
Primary Chronic Venous Disease ◽  
Compression Type

Objectives To describe compliance rates of compression therapy in a cohort of patients with chronic venous disease and also to describe frequent causes of non-compliance. Methods A total of 889 patients with primary chronic venous disease were prescribed compression therapy after being evaluated by vascular surgeons. Subjects had a first visit during which time compression therapy was prescribed in addition to a follow-up visit. Strength of compression, type, prescription duration, and reasons of non-compliance were queried at follow-up. Results Only 31.8% of the patients reported wearing compression therapy as prescribed, 31.4% reported wearing compression most days, 28.3% reported wearing compression intermittently, and 8.5% of the patients reported not wearing compression at all. The main reasons of non-compliance were: uncomfortable (49.4%), too difficult to put on (34.5%), skin problems (itching) (21.5%), and unattractive (19.8%). Conclusions Compliance with compression therapy in chronic venous disease is still a subject of concern as most patients are not using compression therapy as prescribed.

The Significance of Pain in Chronic Venous Disease and its Medical Treatment

2019 ◽  
Vol 17 (3) ◽  
pp. 291-297
Author(s):  
Djordje Radak ◽  
Igor Atanasijević ◽  
Mihailo Nešković ◽  
Esma Isenovic
Keyword(s):  
Varicose Veins ◽  
Compression Therapy ◽  
Interventional Therapy ◽  
Lifestyle Changes ◽  
Chronic Venous Disease ◽  
Venous Disease ◽  
Venous Ulcers ◽  
Venoactive Drugs ◽  
Micronized Purified Flavonoid Fraction ◽  
Flavonoid Fraction

Chronic venous disease (CVeD) is a highly prevalent condition in the general population, and it has a significant impact on quality of life. While it is usually manifested by obvious signs, such as varicose veins and venous ulcers, other symptoms of the disease are less specific. Among the other symptoms, which include heaviness, swelling, muscle cramps and restless legs, pain is the symptom that most frequently compels CVeD patients to seek medical aid. However, there is a substantial discrepancy between pain severity and clinically detectable signs of CVeD, questioned by several opposing studies. Further evaluation is needed to clarify this subject, and to analyse whether pain development predicts objective CVeD progression. </P><P> General management of CVeD starts with advising lifestyle changes, such as lowering body mass index and treating comorbidities. However, the mainstay of treatment is compression therapy, with the additional use of pharmacological substances. Venoactive drugs proved to be the drugs of choice for symptom alleviation and slowing the progression of CVeD, with micronized purified flavonoid fraction being the most effective one. Interventional therapy is reserved for advanced stages of the disease.

The post-thrombotic syndrome

Phlebologie ◽  
2016 ◽  
Vol 45 (04) ◽  
pp. 220-223 ◽  
Author(s):  
F. Pannier ◽  
E. Rabe
Keyword(s):  
Risk Factors ◽  
Weight Loss ◽  
Compression Therapy ◽  
Chronic Venous Disease ◽  
Venous Disease ◽  
Common Complication ◽  
Vein Thrombosis ◽  
Post Thrombotic Syndrome ◽  
Prevention And Treatment ◽  
Deep Vein

SummaryPost-thrombotic syndrome (PTS) is a common complication of deep vein thrombosis (DVT) in the legs. Risk factors include recurrent ipsilateral DVT, proximal vein involvement, persistent occlusion of the deep venous system, obesity, and pre-existing chronic venous disease. Compression therapy, exercise, and weight loss, as well as effective anticoagulation of the initial DVT and secondary thromboprophylaxis, are all important aspects in the prevention and treatment of post-thrombotic syndrome.

Sign in / Sign up

Export Citation Format

Share Document